GERON CORP (GERN) FY2025 10-K Annual Report
GERON CORP (GERN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
GERON CORP FY2025 10-K Analysis
Business Overview
- • Core business model: Biopharmaceutical company focused on cancer therapeutics development
- • No new products, services, or segments introduced or emphasized in this filing year
- • Continued emphasis on corporate governance with established Code of Conduct and Insider Trading Policy
- • No quantitative metrics disclosed in Business section; governance details referenced extensively to Proxy Statement
- • Unusual fact: Entire Business section replaced by governance, ethics, and reference to Proxy Statement, lacking typical operational details
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in MD&A section
- • No segment performance or dollar amounts provided
- • No cash flow, buybacks, dividends, or capital expenditure details reported
- • Risks focus on commercialization, regulatory approvals, clinical trial outcomes, manufacturing, and market acceptance of RYTELO (imetelstat)
- • Forward-looking risks include FDA/EC approval timelines, clinical trial delays, competitive pressures, and macroeconomic impacts on operations
Risk Factors
- • Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
- • Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
- • Supply chain risk: $60 million in manufacturing commitments for RYTELO requiring long lead-times and incurring cancellation penalties
- • Competitive risk: Potential market disruption if RYTELO commercialization fails or competitors advance alternative myelodysplastic syndrome treatments
- • Financial risk: $119.5 million long-term debt principal with covenants and maturity in 2029, plus $141 million net proceeds dilution risk from equity offerings
GERON CORP FY2025 Key Financial MetricsXBRL
Net Income
-$84M
▲ +52.2% YoY
ROE
-37.0%
▲ +2531bp YoY
Total Assets
$571M
▼ -3.9% YoY
EPS (Diluted)
$-0.13
▲ +51.9% YoY
Operating Cash Flow
-$111M
▲ +49.2% YoY
Source: XBRL data from GERON CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on GERON CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.